Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 950-960

  Arigita, Carmen ^a,b   Kersten, Gideon F A ^b   Hazendonk, Ton ^b   Hennink, Wim E ^a   Crommelin, Daan J A ^a   Jiskoot, Wim ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Immunogenicity; Neisseria meningitidis; PorA; Presentation form; Protein conformation

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P1 4; OLIGOSACCHARIDE; OUTER MEMBRANE PROTEIN; PORIN A; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG FORMULATION; DRUG PURIFICATION; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DENATURATION; SPECTROSCOPY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; LIPOSOMES; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; PORINS; PROTEIN CONFORMATION; PROTEIN DENATURATION; SPECTROMETRY, FLUORESCENCE;

EID: 0037435940     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00546-7     Document Type: Conference Paper

References (39)

1. Diaz Romero J., Outschoorn I.M. Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clin. Microbiol. Rev. 7:1994;559-575.
2. Bjune G., Hoiby E.A., Gronnesby J.K.et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
3. Boslego J., Garcia J., Cruz C.et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 13:1995;821-829.
4. De Moraes J.C., Perkins B.A., Camargo M.C.et al. Protective efficacy of serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 340:1992;1074-1078.
5. de Kleijn E.D., de Groot R., Labadie J.et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine. 18:2000;1456-1466.
6. Martin S.L., Borrow R., van der Ley P.et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine. 18:2000;2476-2481.
7. Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM). Bacterial meningitis in The Netherlands annual report 1998. Amsterdam: University of Amsterdam; 1999.
8. Claasen I., Meylis Y., van der Ley P.et al. Production, characterization and control of a Neisseria meningitidis class 1 outer membrane protein containing vesicle vaccine. Vaccine. 14:1996;1001-1008.
9. Fredriksen J.H., Rosenqvist E., Wedege E.et al. Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Annals. 14:1991;67-79.
10. Sierra G.V.G., Campa H.C., Varacel N.M.et al. Vaccines against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:1991;195-210.
11. Van der Ley P., van der Biezen J., Poolman J. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the PorA gene for use in the production of a multivalent vesicle vaccine. Vaccine. 13:1995;401-407.
12. Rouppe-van der Voort E., Schuller M., Holst J.et al. Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine. 18:2000;1334-1343.
13. Verheul A.F.M., Snippe H., Poolman J.T. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol. Rev. 57:1993;43-49.
14. Nurminen M., Butcher S., Iddänpään-Heikkilä I., Wahlström E.et al. The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity. Mol. Microb. 6:1992;2499-2506.
15. Poolman J.T., Hopman C.T.P., Zanen H.C. Immunochemical characterization of outer membrane complexes from Neisseria meningitidis by the SDS-polyacrylamide-gel-electrophoresis-immunoperoxidase technique (SGIP). FEMS Microbiol. Lett. 4:1978;245-248.
16. Dellepiane N., Griffiths E., Milstien J.B. New challenges in assuring vaccine quality. Bull. WHO. 78:2000;155-162.
17. Jansen C., Wiese A., Reubsaet L.et al. Biochemical and biophysical characterization of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim. Biophys. Acta. 1464:2000;284-298.
18. Minetti C.A.S.A., Blake M.S., Remeta D.P. Characterization of the structure, function and conformational stability of PorB class 3 protein from Neisseria meningitidis. J. Biol. Chem. 273:1998;25329-25338.
19. Cowan S.W., Schirmer T., Rummel G.et al. Crystal structures explain functional properties of two E. coli porins. Nature. 358:1992;727-733.
20. Rouppe van der Voort E., van der Ley P., van der Biezen J.et al. Specificity of human bactericidal antibodies against PorA P.17,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64:1996;2745-2751.
21. Ward S.J., Scopes D., Christodoulides M.et al. Expression of Neisseria meningitides class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Micro. Pathol. 21:1996;499-512.
22. Poolman J.T., Timmermans H.A.M., Teerlink T., Seid R.C. Jr. Purification, cyanogen bromide cleavage, and amino terminus sequencing of class 1 and class 3 outer membrane proteins of meningococci. Infect. Immun. 57:1989;1005-1007.
23. Jiskoot W.et al. Preparation of liposomes via detergent removal from mixed micelles by dilution: the effect of bilayer composition and process parameters on liposomes characteristics. Pharma. Wkly. Sci. Ed. 8:1986;259-265.
24. Peterson G.L. A simplification of the protein assay of Lowry et al. which is more generally applicable. Anal. Biochem. 83:1977;346-356.
25. Karlhanis Y.D., Zeltner J.Y., Jackson J.J., Carlo D.J. A new an improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of gram-negative bacteria. Anal. Biochem. 85:1978;595-601.
26. Sambrook S, Fritsch EF, Maniatis T. Ethidium bromide fluorescent quantitation of the amount of double-stranded DNA. In: Nolan E, editor. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 1989;E-5.
27. Lugtenberg B., Meijers J., Peters R., van der Hoek P., van Alphen L. Electrophoretic resolution of the major outer membrane protein of Escherichia coli K-12 into four bands. FEBS Lett. 58:1975;254-258.
28. Lakowicz, JR. Principles of fluorescence spectroscopy. 2nd ed. New York: Plenum Publishers, 1999.
29. van den Ijssel J., Thalen M., Beuvery C., Jiskoot W. Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen bonding ELISA. J. Immunoassay. 18:1997;267-284.
30. Abdillahi H., Poolman J.T. Whole cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol. Lett. 48:1987;367-371.
31. Hoogerhout P., Donders E.M.L.M., van Gaans-van den Brink J.A.M.et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect. Immun. 63:1995;3473-3478.
32. Van der Ley P., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. Topology of outer membrane porins in pathogenic Neisseira spp. Infect. Immun. 59:1991;2963-2971.
33. Brahms S., Brahms J. Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism. J. Mol. Biol. 138:1980;149-178.
34. Wang J., Jarvis G.A., Achtman M.et al. Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis. Infect. Immun. 68:2000;1871-1878.
35. Jansen C., Kuipers B., van der Biezen J.et al. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis. FEMS Imm. Med. Microbiol. 27:2000;227-233.
36. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine. 7:1989;325-328.
37. Steeghs L., Kuipers B., Hamstra H.J.et al. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infect. Immun. 67:1999;4988-4993.
38. Virji M., Heckels J.E. Nonbactericidal antibodies against Neisseria gonorrhoeae: evaluation of their blocking effect on bactericidal antibodies directed against outer membrane antigens. J. Gen. Microbiol. 134:1988;2703-2711.
39. Idänpään-Heikklilä I., Muttilainen S., Wahlström E.et al. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine. 13:1995;1501-1508.